Transport limits cellular entry of hepatic arterially injected 5-[18F]fluoro-2'-deoxyuridine in human intrahepatic tumors. 1994

J R Bading, and E R Sigurdson, and R D Finn, and S D Yeh, and J Ginos, and N E Kemeny, and S M Larson
Nuclear Medicine Research Laboratory, Memorial Sloan-Kettering Cancer Center.

The causes of tumor resistance to hepatic arterially infused fluorodeoxyuridine (FdUrd) are poorly understood. A previous study showed that sufficient arterial perfusion relative to liver is necessary for tumor response. The present study examined the effect of transport on FdUrd flux from arterial blood into tumor cells. Five patients with large intrahepatic tumors (four with colorectal hepatic metastases, one with hepatoma) were given bolus hepatic arterial (HA) injections of [18F]FdUrd, and their livers imaged dynamically with a dual-detector gamma camera. Cellular entry of [18F]FdUrd was inferred by comparison with HA-injected 99mTc diethylenetriaminepentaacetate, an extracellular indicator. The images were analyzed to determine single-pass, blood-into-cell, extraction fractions [E(FdUrd)] and fractional retention of extracted radiolabel vs. time in tumors and liver. Measured E(FdUrd) ranged from 0.75 to 0.91 (mean 0.87 +/- 0.03) in liver and from 0.56 to 0.96 (mean 0.78 +/- 0.08) in tumors. Fluorine-18 was lost from tumors and liver at similar rates following first-pass throughput of unextracted [18F]FdUrd. Less than 10% of the radiolabel remained in tumor or liver by 3.5 hr, implying that little 18F was incorporated into long-lived molecular species within tumor or liver. The observations indicate that, in many cases, limited transport significantly reduces the flux of FdUrd into the cells of intrahepatic tumors, implying that transport must be considered in efforts to increase tumor uptake of hepatic arterially infused FdUrd.

UI MeSH Term Description Entries
D007269 Injections, Intra-Arterial Delivery of drugs into an artery. Injections, Intraarterial,Intra-Arterial Injections,Intraarterial Injections,Injection, Intra-Arterial,Injection, Intraarterial,Injections, Intra Arterial,Intra Arterial Injections,Intra-Arterial Injection,Intraarterial Injection
D007424 Intracellular Fluid The fluid inside CELLS. Fluid, Intracellular,Fluids, Intracellular,Intracellular Fluids
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011877 Radionuclide Imaging The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph. Gamma Camera Imaging,Radioisotope Scanning,Scanning, Radioisotope,Scintigraphy,Scintiphotography,Imaging, Gamma Camera,Imaging, Radionuclide
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females

Related Publications

J R Bading, and E R Sigurdson, and R D Finn, and S D Yeh, and J Ginos, and N E Kemeny, and S M Larson
January 1990, Anticancer research,
J R Bading, and E R Sigurdson, and R D Finn, and S D Yeh, and J Ginos, and N E Kemeny, and S M Larson
May 1988, Proceedings of the National Academy of Sciences of the United States of America,
J R Bading, and E R Sigurdson, and R D Finn, and S D Yeh, and J Ginos, and N E Kemeny, and S M Larson
June 2003, Cancer biotherapy & radiopharmaceuticals,
J R Bading, and E R Sigurdson, and R D Finn, and S D Yeh, and J Ginos, and N E Kemeny, and S M Larson
September 1974, Journal of medicinal chemistry,
J R Bading, and E R Sigurdson, and R D Finn, and S D Yeh, and J Ginos, and N E Kemeny, and S M Larson
January 1984, European journal of nuclear medicine,
J R Bading, and E R Sigurdson, and R D Finn, and S D Yeh, and J Ginos, and N E Kemeny, and S M Larson
January 1990, Journal of neurosurgery,
J R Bading, and E R Sigurdson, and R D Finn, and S D Yeh, and J Ginos, and N E Kemeny, and S M Larson
January 1966, Journal of medicinal chemistry,
J R Bading, and E R Sigurdson, and R D Finn, and S D Yeh, and J Ginos, and N E Kemeny, and S M Larson
June 2001, Japanese journal of clinical oncology,
J R Bading, and E R Sigurdson, and R D Finn, and S D Yeh, and J Ginos, and N E Kemeny, and S M Larson
August 1994, Anti-cancer drugs,
J R Bading, and E R Sigurdson, and R D Finn, and S D Yeh, and J Ginos, and N E Kemeny, and S M Larson
September 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!